Male Cosmetic Genital Surgery
This page covers the elective / aesthetic end of male genital surgery — augmentation phalloplasty, girth enhancement, suspensory-ligament division, suprapubic lipectomy, Penuma, and scrotal aesthetic procedures. Reconstructive operations for trauma, oncologic resection, lichen sclerosus, FGM/C, or congenital anomaly live at 04e Genital Reconstruction; gender-affirming pathway surgery lives at 04k Gender-Affirming Surgery. For the clinical-conditions framework on small penis syndrome (SPS) / penile dysmorphic disorder (PDD) see Small Penis Syndrome.
Society positions and evidence-quality caveat. The SMSNA 2024 position statement notes that the overall quality of evidence for male cosmetic penile-enhancement procedures is low and most should be considered investigational.[1] The ACOG 2020 Committee Opinion and the FIGO 2025 Statement assert that female genital cosmetic procedures are not medically indicated in patients without structural or functional abnormalities, and the FDA 2018 safety communication warned against use of energy-based devices for "vaginal rejuvenation" or cosmetic indications — no such device is FDA-cleared for these uses.[2][3] Mandatory psychological screening for body dysmorphic disorder (BDD) and penile / genital dysmorphic disorder belongs at the front of every consultation.
Decision Framework
The male cosmetic-genital-surgery plan is governed by mandatory psychological screening first, then objective measurement, then first-line non-invasive therapy, then highly selective progression to invasive options. The contemporary anchors are the SMSNA 2024 position statement (Trost) which formally rated the evidence base as low and most procedures as investigational, the Romero-Otero 2021 BJU Int systematic review (n = 4,351 men across 57 studies; standardized criteria for efficacy / safety / satisfaction are missing), the Vyas 2020 PRS SR of augmentation phalloplasty (pooled complication 14.6%; combined length + girth highest), the Furr 2018 J Sex Med referral-center complication series (penile deformity 58%, paradoxical shortening 33%, scrotalization 33%, sexual dysfunction 33%), the Wessells 1996 J Urol complications series, the Elist 2018 + Siegal 2023 + Wilson 2022 Penuma series (the only FDA-cleared cosmetic device; 510(k) clearance), the Yang 2019 / 2020 RCTs of HA vs PLA fillers, the Toussi 2021 J Urol PTT post-prostatectomy RCT, and the Mansfield 2020 + Zhang 2025 + Thomson 2024 BDD-screening framework.[1][4][5][6][7][8][9][10][11][12][13][14]
Mandatory Psychological Screening
| Assessment | Tool | Action if Positive |
|---|---|---|
| BDD screening | BDDQ-AS (7-item, 1–2 min; Australian-regulator-recommended) or BDD-YBOCS (gold-standard diagnostic) | Refer to psychiatry; do not proceed with cosmetic surgery — cosmetic procedures rarely improve core BDD symptoms and are associated with persistent dissatisfaction, symptom exacerbation, and increased legal risk[14][6][15] |
| Penile dysmorphic disorder / SPS | MGSIS (Male Genital Self-Image Scale) + objective penile measurement | Counsel on normal anatomy (Veale nomograms); CBT / psychosexual referral if pain remains; do not equate SPS with surgical indication |
| Realistic-expectation assessment | Clinical interview ± APPSSI questionnaire | Defer surgery if expectations unrealistic; partner / counseling involvement |
| General prevalence framing | Population BDD ~2.5%; cosmetic-surgery cohorts 11.3% | Expect higher BDD prevalence in self-referring cosmetic-augmentation candidates |
Objective Assessment
Measure flaccid length, stretched penile length (SPL), erect length, and circumference using standardized technique. Normal published anchors: flaccid 9.16 cm, SPL 13.24 cm, erect length 13.12 cm, erect circumference 11.66 cm.[8][9] True micropenis is SPL < 7.5 cm in Western populations and warrants endocrine workup. The vast majority of self-referring cosmetic-augmentation candidates have normal-sized, fully functional anatomy and a psychological, not anatomic, primary problem.
First-Line Non-Invasive Options
| Patient Concern | First-Line | Expected Outcome |
|---|---|---|
| Short penile length (cosmetic) | Penile traction therapy (RestoreX preferred) — 30–90 min/day × 3–6 months — the only evidence-based non-invasive technique for penile elongation[16][17] | +1–2 cm flaccid length; modest erect-state effect |
| Apparent shortening from suprapubic adiposity | Weight loss → cryolipolysis (3 sessions) — Azab 2021 SPL 12.10 → 12.88 cm (p < 0.05) | Variable; depends on fat reduction |
| Post-prostatectomy length loss | PTT (RestoreX) ± VED — Toussi 2021 RCT n = 82: PTT +1.6 cm vs +0.3 cm controls (p < 0.01) | Significant + statistically meaningful gains in select indication |
| Psychological distress about normal-size penis | CBT / psychosexual therapy (not surgery) | Improvement in BDD / SPS symptoms without procedural risk |
Invasive-Procedure Selection by Clinical Goal
| Clinical Goal | First-Line | Alternative(s) | Avoid |
|---|---|---|---|
| Girth enhancement (~70.6% of patients) | Hyaluronic-acid (HA) filler injection — best risk-benefit; reversible (hyaluronidase); office-based; Yang 2019/2020 RCTs HA vs PLA both efficacious; Zhang 2022 n = 38 12-mo +2.44 cm flaccid girth; Boiko 2023 n = 132 +1.7 cm midshaft — psychosocial gains do not correlate with size change | PLA filler (longer-lasting collagen-stim; not reversible); Penuma silicone sleeve (only FDA-cleared device; Elist 2018 n = 400 56.7% midshaft increase, Siegal 2023 multicenter n = 49 52% increase, removal in 3%); autologous fat injection (counsel on 30–70% resorption + 58% nodule rate at referral centers) | Non-autologous injectables (silicone, paraffin, Vaseline, PMMA) — strongly discouraged; siliconomas / migration / radical-excision risk |
| Length enhancement (true) | Suspensory-ligament division (SLD) ± V-Y plasty — flaccid +1–4 cm; erect-length gain is minimal or absent; experienced surgeons only | None — sliding / slicing penile-disassembly techniques are PD-specific, not cosmetic; see Sliding & Slicing Techniques (Peyronie's section) | SLD without anti-retraction sutures (scrotalization 33%); SLD in patient who does not understand erect-state gain ≈ 0 |
| Apparent shortening (suprapubic lipodystrophy) | Suprapubic liposuction (Ghanem 2017 — significant SPL improvement) | Open suprapubic lipectomy; diamond-shaped penoplasty (Wang 2025 n = 42 SPL 1.94 → 5.55 cm) | Surgical lipectomy in patient unwilling to address weight regain |
| Penoscrotal webbing (apparent shortening) | Penoscrotal-Web Correction (Z-plasty) at penoscrotal junction — Álvarez Vega 2025 n=100: 98% primary healing, 97% stable at ≥1 yr | Combined SLD + suprapubic lipectomy + Z-plasty for maximal apparent length; ventral phalloplasty + IPP (Miranda-Sousa 2007: 84% increased length perception) | Web-correction without addressing the underlying suprapubic lipodystrophy when present; V-Y plasty in diabetics (OR 4.9 + OR 6.1 dehiscence risk) |
| Scrotal laxity / aesthetic concerns | Reduction scrotoplasty (Thomas 2021 Aesthet Plast Surg algorithm — vertical midline scrotal-skin resection ± Z-plasty for penoscrotal webbing) — see Scrotal Reconstruction Atlas for the full reconstructive scrotal toolkit | Energy-based devices (RF / laser) — no published scrotal-skin clinical evidence | Aesthetic-only intervention without addressing buried-penis or lymphedema disease when present |
| Patient with refractory dissatisfaction after normal outcome | Re-evaluate for BDD; refer to psychiatry; AVOID repeat procedures | Mental-health-led care + CBT | Surgeon-shopping for repeat augmentation |
Procedure-Specific Sub-Comparisons
Girth: HA vs Penuma vs Autologous Fat
| Factor | HA Filler | Penuma (FDA-Cleared) | Autologous Fat |
|---|---|---|---|
| Reversibility | Reversible (hyaluronidase) | Removable (device extraction; ~3% removal rate) | Irreversible (fat-resorption unpredictable) |
| Durability | Temporary (repeat injections needed) | Permanent unless removed | Variable (30–70% resorption) |
| Evidence quality | Best (multiple RCTs — Yang 2019/2020) | Moderate (Elist 2018 single-surgeon n = 400; Siegal 2023 multicenter n = 49) | Lower (mostly retrospective; Furr 2018 referral-center complications 58% deformity / 33% sexual dysfunction) |
| Complication severity | Mild, transient | Moderate (seroma 4.8%, scar 4.5%, infection 3.3%) | Potentially severe (nodules 7–58%, deformity, migration) |
| Setting | Office-based | Operating room | Operating room |
Length: PTT vs Suprapubic Lipectomy vs SLD
| Factor | PTT | Suprapubic Lipectomy | SLD + V-Y |
|---|---|---|---|
| Anatomic basis | None — relies on tissue remodeling | Suprapubic lipodystrophy (true anatomic cause of apparent shortening) | Normal anatomy + desire for length |
| Invasiveness | Non-invasive | Minimal–moderate | Moderate |
| Erect-length gain | Modest | None (apparent only) | Minimal–none |
| Flaccid-length gain | +1–2 cm | Variable (depends on fat volume) | +1–4 cm |
| Risk of intercourse instability | None | None | Yes — loss of suspensory support |
| Compliance requirement | High (daily × months) | None post-op | None post-op |
Postoperative Management
- PTT post-SLD — recommended to prevent retraction and scar contracture; maintains length gains.[1][16]
- Compression dressing — essential after fat injection, Penuma, and HST to minimize seroma and edema.
- Sexual-activity restriction — typically 4–6 weeks post-surgery.
- Standardized follow-up measurements — flaccid / SPL / erect / circumference at 1, 3, 6, 12 mo using the same technique as preoperative.
- HA / PLA maintenance injections — plan for repeat dosing as filler resorbs.
- Weight management — critical for patients post-suprapubic lipectomy / liposuction; weight regain negates results.
Evidence Hierarchy and SMSNA 2024 Recommendations
| Procedure | SMSNA Position | Evidence Level | Recommendation |
|---|---|---|---|
| Penile traction therapy | Supported as first-line non-invasive option | Moderate (RCT data) | First-line for length concerns |
| HA / PLA filler injection | Promising; further study needed | Moderate (multiple RCTs) | Reasonable option for girth with appropriate counseling |
| Penuma silicone implant | Only FDA-cleared cosmetic device; early data promising | Moderate (large single-surgeon series + multicenter) | Acceptable with experienced surgeon and informed consent |
| Suspensory-ligament division | May provide modest flaccid gains; risk of instability | Low (retrospective series) | Caution; experienced surgeons only; mandatory anti-retraction technique |
| Autologous fat injection | Significant complication risk | Low (retrospective; high complication rates at referral centers) | Approach with caution; counsel extensively |
| Non-autologous injectables (silicone / paraffin / Vaseline / PMMA) | Strongly discouraged | N/A — complication reports only | Contraindicated |
Treatment Database
| Procedure | Domain |
|---|---|
| Penile Traction Therapy | Non-Invasive |
| Vacuum Erection Device (VED) | Non-Invasive |
| Cryolipolysis | Non-Invasive |
| Hyaluronic Acid (HA) Filler | Injectable Girth |
| Polylactic Acid (PLA) Filler | Injectable Girth |
| Autologous Fat Injection | Injectable Girth |
| Non-Autologous Injectables | Injectable Girth |
| Suspensory-Ligament Division (SLD) | Surgical Lengthening |
| Suprapubic Lipectomy | Surgical Lengthening |
| V-Y Advancement Plasty | Surgical Lengthening |
| Penoscrotal-Web Z-Plasty | Surgical Lengthening |
| Penuma / Himplant | Surgical Girth |
| Hardrock Sandwich Technique (HST) | Surgical Girth |
| Dermal Fat Grafts / AlloDerm Wraps | Surgical Girth |
| Reduction Scrotoplasty | Scrotal Aesthetic |
| Penoscrotal-Web Correction | Scrotal Aesthetic |
See Also
- Small Penis Syndrome / PDD (Clinical Conditions)
- Penile Traction Therapy
- Penile Implants subsection
- Scrotal Reconstruction (incl. aesthetic-scrotal toolkit)
- Paraffinoma Excision and Penile Resurfacing (siliconoma / paraffin-injection complications)
- Female Cosmetic Genital Surgery
- Foundations — Z-Plasty
References
1. Trost L, Watter DN, Carrier S, et al. Cosmetic penile-enhancement procedures: an SMSNA position statement. J Sex Med. 2024;21(6):573–578. doi:10.1093/jsxmed/qdae045
2. American College of Obstetricians and Gynecologists. Elective female genital cosmetic surgery (Committee Opinion). 2020.
3. US Food and Drug Administration. Statement on efforts to safeguard women's health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for "vaginal rejuvenation". FDA Safety Communication. 2018.
4. Romero-Otero J, Manfredi C, Ralph D, et al. Non-invasive and surgical penile-enhancement interventions for aesthetic or therapeutic purposes: a systematic review. BJU Int. 2021;127(3):269–291. doi:10.1111/bju.15145
5. Vyas KS, Abu-Ghname A, Banuelos J, Morrison SD, Manrique O. Aesthetic augmentation phalloplasty: a systematic review of techniques and outcomes. Plast Reconstr Surg. 2020;146(5):995–1006. doi:10.1097/PRS.0000000000007249
6. Mansfield AK. Genital manifestations of body dysmorphic disorder in men: a review. Fertil Steril. 2020;113(1):16–20. doi:10.1016/j.fertnstert.2019.11.028
7. Vardi Y, Har-Shai Y, Gil T, Gruenwald I. A critical analysis of penile enhancement procedures for patients with normal penile size: surgical techniques, success, and complications. Eur Urol. 2008;54(5):1042–1050. doi:10.1016/j.eururo.2008.07.080
8. García Gómez B, Alonso Isa M, García Rojo E, Fiorillo A, Romero Otero J. Penile-length-augmentation surgical and non-surgical approaches for aesthetic purposes. Int J Impot Res. 2022;34(4):332–336. doi:10.1038/s41443-021-00488-7
9. Furr J, Hebert K, Wisenbaugh E, Gelman J. Complications of genital-enlargement surgery. J Sex Med. 2018;15(12):1811–1817. doi:10.1016/j.jsxm.2018.10.007
10. Wessells H, Lue TF, McAninch JW. Complications of penile lengthening and augmentation seen at one referral center. J Urol. 1996;155(5):1617–1620.
11. Elist JJ, Valenzuela R, Hillelsohn J, Feng T, Hosseini A. A single-surgeon retrospective and preliminary evaluation of the safety and effectiveness of the Penuma silicone-sleeve implant for elective cosmetic correction of the flaccid penis. J Sex Med. 2018;15(9):1216–1223. doi:10.1016/j.jsxm.2018.07.006
12. Siegal AR, Zisman A, Sljivich M, Razdan S, Valenzuela RJ. Outcomes of a single center's initial experience with the Penuma penile implant. Urology. 2023;171:236–243. doi:10.1016/j.urology.2022.07.066
13. Wilson SK, Picazo AL. Update on the Penuma — an FDA-cleared penile implant for aesthetic enhancement of the flaccid penis. Int J Impot Res. 2022;34(4):369–374. doi:10.1038/s41443-021-00510-y
14. Thomson DR, Thomson NEV, Southwick G. Screening for body dysmorphic disorder in plastic-surgery patients. Aesthet Plast Surg. 2024;48(14):2738–2743. doi:10.1007/s00266-024-03959-6
15. Zhang Y, Lyu Y, Liu D, et al. Exploring the prevalence and etiological factors of body dysmorphic disorder in cosmetic-surgery populations. Aesthet Plast Surg. 2025;49(14):4082–4086. doi:10.1007/s00266-024-04616-8
16. Sultana A, Grice P, Vukina J, Pearce I, Modgil V. Indications and characteristics of penile-traction and vacuum-erection devices. Nat Rev Urol. 2022;19(2):84–100. doi:10.1038/s41585-021-00532-7
17. Toussi A, Ziegelmann M, Yang D, et al. Efficacy of a novel penile-traction device in improving penile length and erectile function post-prostatectomy: results from a single-center randomized, controlled trial. J Urol. 2021;206(2):416–426. doi:10.1097/JU.0000000000001792